Advertisement

Topics

Late-Stage Study Evaluating Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

09:28 EDT 5 Jul 2017 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its primary endpoint at a planned interim analysis, demonstrating superior recurrence-free survival (RFS) in patients receiving Opdivo compared to Yervoy. “These topline …

Original Article: Late-Stage Study Evaluating Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "Late-Stage Study Evaluating Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...